INVESTORS & MEDIA
Corporate Governance
Corporate Governance
| Date | Name | Title | Type | Shares Traded | Price |
|---|---|---|---|---|---|
| Dec 31, 2020 |
Director, President and Chief Scientific
Trans History: 552
|
Director, President and Chief Scientific | Other acquisition or disposition | -- | -- |
| Dec 31, 2020 |
Director, President and Chief Scientific
Trans History: 552
|
Director, President and Chief Scientific | Other acquisition or disposition | -- | -- |
| Dec 31, 2020 |
Director, President and Chief Scientific
Trans History: 552
|
Director, President and Chief Scientific | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 620,270 | -- |
| Dec 30, 2020 |
Director, President and Chief Scientific
Trans History: 552
|
Director, President and Chief Scientific | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 240,000 | $52.03 |
| Dec 30, 2020 |
Director, President and Chief Scientific
Trans History: 552
|
Director, President and Chief Scientific | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 130,714 | $483.25 |
| Dec 30, 2020 |
Director, President and Chief Scientific
Trans History: 552
|
Director, President and Chief Scientific | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 158,079 | $52.03 |
| Dec 30, 2020 |
Director, President and Chief Scientific
Trans History: 552
|
Director, President and Chief Scientific | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 86,096 | $483.25 |
| Dec 30, 2020 |
Director, President and Chief Scientific
Trans History: 552
|
Director, President and Chief Scientific | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 240,000 | -- |
| Dec 30, 2020 |
Director, President and Chief Scientific
Trans History: 552
|
Director, President and Chief Scientific | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 158,079 | -- |
| Dec 11, 2020 |
VP Controller
Trans History: 163
|
VP Controller | Other acquisition or disposition | -- | -- |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.